March 22, 2019

Deal Snapshot: Alexion Pharmaceuticals & Affibody

Median deal values by quarter

  • Deal Headline: Alexion and Affibody Announce Partnership (20 Mar 2019)
  • Licensee: Alexion Pharmaceuticals
  • Licensor: Affibody
  • Therapeutic Area: Autoimmune Diseases
  • Asset: ABY-039
  • Technology: Bivalent antibody-mimetic inhibitor
  • Target: Neonatal Fc receptor (FcRn)
  • Phase: Phase I
  • Deal Type: Licensing
  • Other: "Affibody has the option to co-promote ABY-039 in the U.S. and will lead clinical development for an undisclosed indication."

  • Upfront: USD 25M
  • Milestones: USD 625M
  • Total Deal Value: USD 650M
  • Royalties: Tiered, low double-digit
  • Territory: Worldwide

Alexion Pharmaceuticals Key BD Contacts

Alexion Pharmaceuticals Deal Activity by Therapeutic Area (Last 3 Years)

Recent deal activity by disease area

Recent In-Licensing Deals and Acquisitions:

Alexion Pharmaceuticals Pipeline Composition

Pipeline composition, disease areas

Alexion Lead Autoimmune Assets

Asset Indication Stage
Soliris (eculizumab) Relapsing Neuromyelitis Optica Spectrum Disorder Phase III (Marketed for PNH, aHUS, and gMG)

Business profiles tailored to your asset.